Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer Pharmaceutical Investing
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Life Science Investing
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Life Science Investing
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026 Life Science Investing
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer Pharmaceutical Investing
Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions Pharmaceutical Investing
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 Life Science Investing
BriaCell to Present Positive Clinical Data for Bria-IMT and Preclinical Data for Next Generation Bria-OTS+ Personalized Immunotherapy at the 2026 AACR Conference Biotech Investing
Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A Pharmaceutical Investing
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants Life Science Investing
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update Life Science Investing
